Skip to main content
Premium Trial:

Request an Annual Quote

Friz Biochem Raises 3M to Develop DNA Microarray Platform Further

NEW YORK, March 28 - Friz Biochem of Munich has raised €3 million in the first closing of a Series B financing round, the company said today.


Existing shareholder Global Life Science Ventures led the round, joined by DRF Beteiligungsgesellschaft as a co-investor.


The company expects to raise additional funds, including soft loans, in a second closing.


Friz develops a DNA microarray platform with an electrical readout technology. It plans to use the funding to establish pilot production capabilities and to validate the arrays in the areas of food pathogens and clinical diagnosis.


For further information, see the company statement.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.